{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:56:59Z","timestamp":1793246219822,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.dmd.2025.100036","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:22:35Z","timestamp":1736839355000},"page":"100036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7622-6259","authenticated-orcid":false,"given":"Helen","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Sechaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Pelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Einolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100036_bib1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1124\/dmd.111.040634","article-title":"Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions","volume":"39","author":"Chen","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/bdd.2159","article-title":"Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling\u2014a case example","volume":"39","author":"Chen","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/psp4.12515","article-title":"Physiologically-based pharmacokinetic model-informed drug development for fenebrutinib: understanding complex drug-drug interactions","volume":"9","author":"Chen","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib4","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13318-016-0383-9","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin and atorvastatin to predict drug-drug interactions (DDIs)","volume":"42","author":"Duan","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100036_bib6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug\u2013drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-014-1675-0","article-title":"Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin","volume":"70","author":"Dutreix","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib8","series-title":"Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation","year":"2016"},{"key":"10.1016\/j.dmd.2025.100036_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/dmd.121.000356","volume":"49","author":"Eng","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib37","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dmd.2025.100036_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/dmd.117.078006","article-title":"Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex cyp3a4 drug-drug interaction potential: a case example of midostaurin","volume":"46","author":"Gu","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.116.072744","article-title":"Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug","volume":"45","author":"He","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bbrc.2014.01.176","article-title":"Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection","volume":"446","author":"Ikegami","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmd.2025.100036_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100036_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cpt.1599","article-title":"Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI","volume":"107","author":"Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100036_bib18","doi-asserted-by":"crossref","DOI":"10.1517\/17425255.4.2.137","article-title":"Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing","volume":"4","author":"Kacevska","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmd.2025.100036_bib19","article-title":"Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in m ice","volume":"00","author":"Kawahara","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.dmd.2025.100036_bib20","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in\u00a0vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmd.2025.100036_bib21","doi-asserted-by":"crossref","first-page":"1628S","DOI":"10.1093\/ajcn\/65.5.1628S","article-title":"Individual fatty acids on plasma lipids and lipoproteins: human studies","volume":"65","author":"Kris-Etherton","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.dmd.2025.100036_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/psp4.12479","article-title":"Consideration of a credibility assessment framework in model-informed drug development: potential application to physiologically-based pharmacokinetic modeling and simulation","volume":"9","author":"Kuemmel","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2014.18","article-title":"Evaluation of 4beta hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model","volume":"3","author":"Leil","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib24","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/cts.13272","article-title":"Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug\u2013drug interactions from coproporphyrin I to probe drugs","volume":"15","author":"Mochizuki","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2025.100036_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib26","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1124\/dmd.120.000149","article-title":"Calibrating the in vitro\u2013in vivo correlation for OATP-mediated drug-drug interactions with rosuvastatin using static and PBPK models","volume":"48","author":"Sane","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-023-04635-3","article-title":"Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants","volume":"93","author":"Sechaud","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-024-04683-3","article-title":"Effect of midostaurin on the pharmacokinetics of P-gp, BCRP and CYP2D6 substrates: assessing potential drug-drug interaction in healthy participants","volume":"94","author":"Sechaud","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmd.2025.100036_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100036_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/dmd.113.054171","article-title":"Association of plasma concentrations of 4\u03b2-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients","volume":"42","author":"Suzuki","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100036_bib31","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1693","article-title":"PBPK models for evaluating membrane transporter mediated DDIs: current capabilities, case studies, future opportunities and recommendations","volume":"107","author":"Taskar","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100036_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cpt.2670","article-title":"Clinical relevance of hepatic and renal P-gp\/BCRP inhibition of drugs: an International Transporter Consortium perspective","volume":"112","author":"Taskar","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100036_bib33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/ajcn\/63.6.897","article-title":"Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men","volume":"63","author":"Temme","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.dmd.2025.100036_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in\u00a0vitro-in\u00a0vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2025.100036_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/0003088-200847120-00005","article-title":"A\u00a0mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects","volume":"47","author":"Yin","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100036_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/psp4.12315","article-title":"Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics","volume":"7","author":"Yoshida","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:16:44Z","timestamp":1746116204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0090955625001114"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100036","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100036"}}